Bristol Myers Squibb looks to Texas; Novartis looks to remove CDMO from its Slovenia campus; and more
Plus, news about Gilead and West Pharma:
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Confirm Endpoints as a trusted biopharma news source
Bioscience & Technology Business Center
The University of Kansas
Novartis terminates plant contract with Chinese CDMO Porton, threatens $64M in legal claims
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Novartis, AbbVie plan summer layoffs on opposite coasts
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
UCB digs deeper into Bimzelx’s psoriatic arthritis win over Skyrizi
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
EU and US advisers split over AstraZeneca breast cancer drug
AbbVie, GSK race up patient reputation leaderboard in the UK
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
Design Therapeutics shares Phase 1/2 data in Friedreich ataxia; Vincentage Pharma, a new China obesity player, emerges with Phase…
Pfizer’s experimental 25-valent pneumococcal shot beats Prevnar 20; Relay Therapeutics charts $175M offering; Lilly to pay up to…
A Novartis cross-border partnership is turning into a standoff. | A Novartis cross-border partnership is turning into a standoff.…
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
